Literature DB >> 9008168

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

M S O'Reilly1, T Boehm, Y Shing, N Fukai, G Vasios, W S Lane, E Flynn, J R Birkhead, B R Olsen, J Folkman.   

Abstract

We previously identified the angiogenesis inhibitor angiostatin. Using a similar strategy, we have identified endostatin, an angiogenesis inhibitor produced by hemangioendothelioma. Endostatin is a 20 kDa C-terminal fragment of collagen XVIII. Endostatin specifically inhibits endothelial proliferation and potently inhibits angiogenesis and tumor growth. By a novel method of sustained release, E. coli-derived endostatin was administered as a nonrefolded suspension. Primary tumors were regressed to dormant microscopic lesions. Immunohistochemistry revealed blocked angiogenesis accompanied by high proliferation balanced by apoptosis in tumor cells. There was no toxicity. Together with angiostatin data, these findings validate a strategy for identifying endogenous angiogenesis inhibitors, suggest a theme of fragments of proteins as angiogenesis inhibitors, and demonstrate dormancy therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008168     DOI: 10.1016/s0092-8674(00)81848-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  967 in total

Review 1.  Influence of host microvascular environment on tumour vascular endothelium.

Authors:  M Kubitza; L Hickey; W G Roberts
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

Review 2.  Anticancer drug targets: approaching angiogenesis.

Authors:  E Keshet; S A Ben-Sasson
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 3.  Angiogenic molecules and mechanisms in breast cancer.

Authors:  I Wu; M A Moses
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

Review 4.  Angiogenesis inhibitors.

Authors:  T R Tennant; C W Rinker-Schaeffer; W M Stadler
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 5.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 6.  Angiogenesis.

Authors:  C D Kontos; B H Annex
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.113

Review 7.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

8.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.

Authors:  C J Kuo; F Farnebo; E Y Yu; R Christofferson; R A Swearingen; R Carter; H A von Recum; J Yuan; J Kamihara; E Flynn; R D'Amato; J Folkman; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 9.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

Review 10.  Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules.

Authors:  G E Davis; K J Bayless; M J Davis; G A Meininger
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.